{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:35:10Z","timestamp":1790728510759,"version":"4.1.0"},"reference-count":88,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.beha.2020.101141","type":"journal-article","created":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T13:54:49Z","timestamp":1578923689000},"page":"101141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["CAR T and CAR NK cells in multiple myeloma: Expanding the targets"],"prefix":"10.1016","volume":"33","author":[{"given":"Urvi A.","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sham","family":"Mailankody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.beha.2020.101141_bib1","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.beha.2020.101141_bib2","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1038\/leu.2016.380","article-title":"Trends in overall survival and costs of multiple myeloma","volume":"31","author":"Fonseca","year":"2017","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.beha.2020.101141_bib3","doi-asserted-by":"crossref","first-page":"5453","DOI":"10.1158\/1078-0432.CCR-16-0868","article-title":"Immune therapies in multiple myeloma","volume":"22","author":"Kumar","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"10027","key":"10.1016\/j.beha.2020.101141_bib4","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.beha.2020.101141_bib5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2016-03-705210","article-title":"Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma","volume":"128","author":"Usmani","year":"2016","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2020.101141_bib6","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.beha.2020.101141_bib7","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00277-018-03592-9","article-title":"Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma","volume":"98","author":"Ma","year":"2019","journal-title":"Ann Hematol"},{"issue":"9","key":"10.1016\/j.beha.2020.101141_bib8","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1080\/10428194.2017.1393668","article-title":"CAR T cell therapy for multiple myeloma: where are we now and where are we headed?","volume":"59","author":"Ghosh","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.beha.2020.101141_bib9","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/jgm.2604","article-title":"Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions","volume":"14","author":"Curran","year":"2012","journal-title":"J Gene Med"},{"key":"10.1016\/j.beha.2020.101141_bib10","doi-asserted-by":"crossref","first-page":"16011","DOI":"10.1038\/mto.2016.11","article-title":"Toxicity and management in CAR T-cell therapy","volume":"3","author":"Bonifant","year":"2016","journal-title":"Mol Ther Oncolytics"},{"issue":"3","key":"10.1016\/j.beha.2020.101141_bib11","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/PPO.0000000000000379","article-title":"Multiple myeloma, targeting B-cell maturation antigen with chimeric antigen receptor T-cells","volume":"25","author":"Shah","year":"2019","journal-title":"Cancer J"},{"issue":"8","key":"10.1016\/j.beha.2020.101141_bib12","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2020.101141_bib13","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1038\/bcj.2015.3","article-title":"B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy?","volume":"5","author":"Hengeveld","year":"2015","journal-title":"Blood Canc J"},{"key":"10.1016\/j.beha.2020.101141_bib14","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3389\/fimmu.2018.01821","article-title":"Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy","volume":"9","author":"Cho","year":"2018","journal-title":"Front Immunol"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2020.101141_bib15","first-page":"2755","article-title":"B- cell maturation antigen is exclusively expressed in a wide range of B-cell and plasma cell neoplasm and in a potential therapeutic target for bcma directed therapies","volume":"130","author":"Khattar","year":"2017","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.beha.2020.101141_bib16","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.beha.2020.101141_bib17","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an anti\u2013B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.beha.2020.101141_bib18","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1089\/hum.2018.001","article-title":"Effective targeting of multiple B-cell maturation antigen-expressing hematological malignances by anti-B-cell maturation antigen chimeric antigen receptor T cells","volume":"29","author":"Friedman","year":"2018","journal-title":"Hum Gene Ther"},{"issue":"18","key":"10.1016\/j.beha.2020.101141_bib19","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"issue":"15_suppl","key":"10.1016\/j.beha.2020.101141_bib20","doi-asserted-by":"crossref","first-page":"8007","DOI":"10.1200\/JCO.2018.36.15_suppl.8007","article-title":"bb2121 anti-BCMA CAR T-cell therapy in patients with relapsed\/refractory multiple myeloma: updated results from a multicentre phase I study","volume":"36","author":"Raje","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.beha.2020.101141_bib21","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.ymthe.2018.03.016","article-title":"Development and evaluation of an optimal human single-chain variable fragment-derived BCMA-targeted CAR T cell vector","volume":"26","author":"Smith","year":"2018","journal-title":"Mol Ther"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2020.101141_bib22","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2018-99-119717","article-title":"Clinical responses and pharmacokinetics of MCARH171, a human-derived bcma targeted CAR T cell therapy in relapsed\/refractory multiple myeloma: final results of a phase I clinical trial","volume":"132","author":"Mailankody","year":"2018","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2020.101141_bib23","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1182\/blood-2018-99-113548","article-title":"JCARH125, anti-BCMA CAR T-cell therapy for relapsed\/refractory multiple myeloma: initial proof of concept results from a phase 1\/2 multicenter study (EVOLVE)","volume":"132","author":"Mailankody","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2020.101141_bib24","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Investig"},{"issue":"5","key":"10.1016\/j.beha.2020.101141_bib25","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukaemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.beha.2020.101141_bib26","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","article-title":"A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma","volume":"11","author":"Zhao","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2020.101141_bib27","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1182\/blood-2018-99-110548","article-title":"Updated analysis of a phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B-cell maturation antigen, in patients with relapsed\/refractory multiple myeloma","volume":"132","author":"Zhao","year":"2018","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2020.101141_bib28","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1182\/blood-2018-99-112786","article-title":"Durable remission achieved from bcma-directed CAR-T therapy against relapsed or refractory multiple myeloma","volume":"132","author":"Liu","year":"2018","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2020.101141_bib29","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1182\/blood-2018-99-113220","article-title":"Low dose of human scFv-derived BCMA-targeted CAR-T cells achieved fast response and high complete remission in patients with relapsed\/refractory multiple myeloma","volume":"132","author":"Jiang","year":"2018","journal-title":"Blood"},{"issue":"13 Supplement","key":"10.1016\/j.beha.2020.101141_bib30","doi-asserted-by":"crossref","first-page":"4979","DOI":"10.1158\/1538-7445.AM2017-4979","article-title":"Abstract 4979: development of KITE-585: a fully human BCMA CAR T-cell therapy for the treatment of multiple myeloma","volume":"77","author":"Adams","year":"2017","journal-title":"Cancer Res"},{"issue":"15_suppl","key":"10.1016\/j.beha.2020.101141_bib31","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS3103","article-title":"A phase 1 multicentre study evaluating KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed\/refractory multiple myeloma","volume":"36","author":"Cornell","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.beha.2020.101141_bib32","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1179\/1607845413Y.0000000079","article-title":"GPRC5D is a promising marker for monitoring the tumour load and to target multiple myeloma cells","volume":"18","author":"Cohen","year":"2013","journal-title":"Hematology"},{"issue":"9","key":"10.1016\/j.beha.2020.101141_bib33","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/j.1365-2362.2012.02679.x","article-title":"Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma","volume":"42","author":"Atamaniuk","year":"2012","journal-title":"Eur J Clin Investig"},{"issue":"485","key":"10.1016\/j.beha.2020.101141_bib34","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.beha.2020.101141_bib35","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jocit.2014.11.001","article-title":"CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma","volume":"2","author":"Guo","year":"2016","journal-title":"J Cell Immunother"},{"issue":"1","key":"10.1016\/j.beha.2020.101141_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0145-2126(00)00093-X","article-title":"Human CD38: a (r)evolutionary story of enzymes and receptors","volume":"25","author":"Deaglio","year":"2001","journal-title":"Leuk Res"},{"issue":"5","key":"10.1016\/j.beha.2020.101141_bib37","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3324\/haematol.2015.137620","article-title":"Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma","volume":"101","author":"Drent","year":"2016","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.beha.2020.101141_bib38","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/j.ymthe.2017.04.024","article-title":"A rational strategy for reducing on-target off-tumor effects of CD38-chimeric antigen receptors by affinity optimization","volume":"25","author":"Drent","year":"2017","journal-title":"Mol Ther"},{"issue":"8","key":"10.1016\/j.beha.2020.101141_bib39","first-page":"1637","article-title":"CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma","volume":"7","author":"Malaer","year":"2017","journal-title":"Am J Cancer Res"},{"issue":"26","key":"10.1016\/j.beha.2020.101141_bib40","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1182\/blood-2017-04-778423","article-title":"SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7(+) normal lymphocytes","volume":"130","author":"Gogishvili","year":"2017","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2020.101141_bib41","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jcyt.2018.05.001","article-title":"Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy","volume":"20","author":"Murad","year":"2018","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.beha.2020.101141_bib42","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1158\/2326-6066.CIR-18-0307","article-title":"Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML\/MDS and multiple myeloma","volume":"7","author":"Baumeister","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2020.101141_bib43","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/blood-2018-99-114522","article-title":"NKG2D-CAR transduced primary natural killer cells efficiently target multiple myeloma cells","volume":"132","author":"Leivas","year":"2018","journal-title":"Blood"},{"issue":"8 Supplement","key":"10.1016\/j.beha.2020.101141_bib44","first-page":"3499","article-title":"Abstract 3499: CD56 targeted chimeric antigen receptors for immunotherapy of multiple myeloma","volume":"72","author":"Benjamin","year":"2012"},{"issue":"1","key":"10.1016\/j.beha.2020.101141_bib45","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1038\/s41467-019-10948-w","article-title":"Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T","volume":"10","author":"Nerreter","year":"2019","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.beha.2020.101141_bib46","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1056\/NEJMoa1504542","article-title":"Chimeric antigen receptor T cells against CD19 for multiple myeloma","volume":"373","author":"Garfall","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.beha.2020.101141_bib47","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.127684","article-title":"Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma","volume":"4","author":"Garfall","year":"2019","journal-title":"JCI Insight"},{"issue":"7","key":"10.1016\/j.beha.2020.101141_bib48","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1172\/JCI86000","article-title":"Clinical responses with T lymphocytes targeting malignancy-associated \u03ba light chains","volume":"126","author":"Ramos","year":"2016","journal-title":"J Clin Investig"},{"key":"10.1016\/j.beha.2020.101141_bib49","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/B978-0-12-386509-0.00003-X","article-title":"Retrovirus and lentivirus vector design and methods of cell conditioning","volume":"507","author":"Cooray","year":"2012","journal-title":"Methods Enzymol"},{"issue":"1","key":"10.1016\/j.beha.2020.101141_bib50","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1186\/s12967-016-1047-x","article-title":"Retroviral vectors and transposons for stable gene therapy: advances, current challenges and perspectives","volume":"14","author":"Vargas","year":"2016","journal-title":"J Transl Med"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2020.101141_bib51","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1182\/blood-2018-99-111419","article-title":"Efficacy and safety of P-Bcma-101 CAR-T cells in patients with relapsed\/refractory (r\/r) multiple myeloma (MM)","volume":"132","author":"Gregory","year":"2018","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.beha.2020.101141_bib52","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.V128.22.2127.2127","article-title":"A novel bcma-specific, centyrin-based CAR-T product for the treatment of multiple myeloma","volume":"128","author":"Hermanson","year":"2016","journal-title":"Blood"},{"issue":"544","key":"10.1016\/j.beha.2020.101141_bib53","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aat6753","article-title":"Phosphoproteomic analysis of chimeric antigen receptor signalling reveals kinetic and quantitative differences that affect cell function","volume":"11","author":"Salter","year":"2018","journal-title":"Sci Signal"},{"issue":"7655","key":"10.1016\/j.beha.2020.101141_bib54","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nature22395","article-title":"Therapeutic T cell engineering","volume":"545","author":"Sadelain","year":"2017","journal-title":"Nature"},{"issue":"355","key":"10.1016\/j.beha.2020.101141_bib55","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"issue":"10","key":"10.1016\/j.beha.2020.101141_bib56","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1038\/leu.2017.57","article-title":"Fully human CD19-specific chimeric antigen receptors for T-cell therapy","volume":"31","author":"Sommermeyer","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.beha.2020.101141_bib57","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1182\/blood-2010-07-294520","article-title":"Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells","volume":"117","author":"Lamers","year":"2011","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2020.101141_bib58","first-page":"504","article-title":"T cells expressing anti-B-cell maturation antigen (BCMA) chimeric antigen receptors with antigen recognition domains made up of only single human heavy chain variable domains specifically recognize bcma and eradicate tumors in mice","volume":"130","author":"Lam","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2020.101141_bib59","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Investig"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2020.101141_bib60","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1182\/blood-2018-99-111576","article-title":"Improved expansion and function of CAR T cell products from cultures initiated at defined CD4:CD8 ratios","volume":"132","author":"Lee","year":"2018","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2020.101141_bib61","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1182\/blood-2018-99-117729","article-title":"Fully human bcma targeted chimeric antigen receptor T cells administered in a defined composition demonstrate potency at low doses in advanced stage high risk multiple myeloma","volume":"132","author":"Green","year":"2018","journal-title":"Blood"},{"issue":"2 Pt C","key":"10.1016\/j.beha.2020.101141_bib62","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.molimm.2015.07.026","article-title":"Feeding an army: the metabolism of T cells in activation, anergy, and exhaustion","volume":"68","author":"Delgoffe","year":"2015","journal-title":"Mol Immunol"},{"issue":"9","key":"10.1016\/j.beha.2020.101141_bib63","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1158\/1535-7163.MCT-17-1097","article-title":"Strategies to address chimeric antigen receptor tonic signalling","volume":"17","author":"Ajina","year":"2018","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"10.1016\/j.beha.2020.101141_bib64","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.it.2013.10.001","article-title":"Tolerance and exhaustion: defining mechanisms of T cell dysfunction","volume":"35","author":"Schietinger","year":"2014","journal-title":"Trends Immunol"},{"issue":"7655","key":"10.1016\/j.beha.2020.101141_bib65","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nature22367","article-title":"Chromatin states define tumour-specific T cell dysfunction and reprogramming","volume":"545","author":"Philip","year":"2017","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.beha.2020.101141_bib66","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.molmed.2016.10.002","article-title":"Cell-intrinsic barriers of T cell-based immunotherapy","volume":"22","author":"Ghoneim","year":"2016","journal-title":"Trends Mol Med"},{"issue":"23","key":"10.1016\/j.beha.2020.101141_bib67","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.95103","article-title":"Inhibition of AKT signalling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy","volume":"2","author":"Klebanoff","year":"2017","journal-title":"JCI Insight"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2020.101141_bib68","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1182\/blood-2018-99-116953","article-title":"Initial results from a phase 1 clinical study of bb21217, a next-generation anti bcma CAR T therapy","volume":"132","author":"Shah","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.beha.2020.101141_bib69","doi-asserted-by":"crossref","first-page":"16015","DOI":"10.1038\/mto.2016.15","article-title":"Clinical manufacturing of CAR T cells: foundation of a promising therapy","volume":"3","author":"Wang","year":"2016","journal-title":"Mol Ther Oncolytics"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2020.101141_bib70","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1182\/blood-2018-99-115319","article-title":"Clinical predictors of T cell fitness for CAR T cell manufacturing and efficacy in multiple myeloma","volume":"132","author":"Dancy","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2020.101141_bib71","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1158\/1078-0432.CCR-17-0344","article-title":"Lenalidomide enhances the function of CS1 chimeric antigen receptor-redirected T cells against multiple myeloma","volume":"24","author":"Wang","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2020.101141_bib72","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1182\/blood-2018-99-119514","article-title":"PD-1 inhibitor combinations as salvage therapy for relapsed\/refractory multiple myeloma (MM) patients progressing after bcma-directed CAR T cells","volume":"132","author":"Bernabei","year":"2018","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2020.101141_bib73","first-page":"505","article-title":"Safety and efficacy of B-cell maturation antigen (BCMA)-Specific chimeric antigen receptor T cells (CART-BCMA) with cyclophosphamide conditioning for refractory multiple myeloma (MM)","volume":"130","author":"Cohen","year":"2017","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.beha.2020.101141_bib74","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1182\/blood.2019000050","article-title":"gamma-secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma","volume":"134","author":"Pont","year":"2019","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2020.101141_bib75","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","article-title":"A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial","volume":"6","author":"Yan","year":"2019","journal-title":"Lancet Haematol"},{"issue":"7","key":"10.1016\/j.beha.2020.101141_bib76","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1182\/blood-2017-05-781351","article-title":"An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma","volume":"131","author":"Lee","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2020.101141_bib77","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/leu.2017.302","article-title":"A compound chimeric antigen receptor strategy for targeting multiple myeloma","volume":"32","author":"Chen","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2020.101141_bib78","series-title":"Optimal dual-targeted CAR construct simultaneously targeting bcma and GPRC5D prevents bcma-escape driven relapse in multiple myeloma blood","author":"Fernandez de Larrea","year":"2019"},{"issue":"10","key":"10.1016\/j.beha.2020.101141_bib79","doi-asserted-by":"crossref","DOI":"10.3390\/cells7100155","article-title":"Allogeneic CAR-T cells: more than ease of access?","volume":"7","author":"Graham","year":"2018","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.beha.2020.101141_bib80","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.ymthe.2019.04.001","article-title":"Preclinical evaluation of allogeneic CAR T cells targeting BCMA for the treatment of multiple myeloma","volume":"27","author":"Sommer","year":"2019","journal-title":"Mol Ther"},{"issue":"2","key":"10.1016\/j.beha.2020.101141_bib81","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.beha.2018.03.001","article-title":"Off the shelf T cell therapies for hematologic malignancies","volume":"31","author":"McCreedy","year":"2018","journal-title":"Best Pract Res Clin Haematol"},{"issue":"4","key":"10.1016\/j.beha.2020.101141_bib82","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.ymthe.2017.02.005","article-title":"Integration of a CD19 CAR into the TCR alpha chain locus streamlines production of allogeneic gene-edited CAR T cells","volume":"25","author":"MacLeod","year":"2017","journal-title":"Mol Ther"},{"issue":"Suppl 2","key":"10.1016\/j.beha.2020.101141_bib83","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/s41409-019-0601-6","article-title":"Adoptive cell therapy using engineered natural killer cells","volume":"54","author":"Rezvani","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.beha.2020.101141_bib84","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.ymthe.2017.06.012","article-title":"Engineering natural killer cells for cancer immunotherapy","volume":"25","author":"Rezvani","year":"2017","journal-title":"Mol Ther"},{"issue":"2","key":"10.1016\/j.beha.2020.101141_bib85","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2017.226","article-title":"Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity","volume":"32","author":"Liu","year":"2018","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.beha.2020.101141_bib86","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.molonc.2013.12.001","article-title":"Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells","volume":"8","author":"Jiang","year":"2014","journal-title":"Mol Oncol"},{"issue":"4","key":"10.1016\/j.beha.2020.101141_bib87","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/leu.2013.279","article-title":"CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma","volume":"28","author":"Chu","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2020.101141_bib88","series-title":"NKG2D and BCMA-CAR NK cells efficiently eliminate multiple myeloma cells. A comprehensive comparison between two clinically relevant CARs","author":"Maroto-Mart\u00edn","year":"2019"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692620300025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692620300025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:06:21Z","timestamp":1761498381000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692620300025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":88,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S1521692620300025"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2020.101141","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR T and CAR NK cells in multiple myeloma: Expanding the targets","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2020.101141","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101141"}}